These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 11428472)

  • 1. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials and lipid guidelines for type II diabetes.
    Prisant LM
    J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
    Maki KC; Dicklin MR; Davidson MH; Doyle RT; Ballantyne CM;
    Am J Cardiol; 2010 May; 105(10):1409-12. PubMed ID: 20451686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH; Huijberts MS
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):761-5. PubMed ID: 11346911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy].
    Martínez-Castelao A; Ramos R; González MT; Castiñeiras MJ
    Nefrologia; 2002; 22 Suppl 1():51-8. PubMed ID: 11987671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia.
    Abdel-Gayoum AG
    Saudi Med J; 2004 Feb; 25(2):207-11. PubMed ID: 14968220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
    Cooke CE; Hammerash WJ
    Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia in type 2 diabetes.
    Krauss RM; Siri PW
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.